GlassScriptPhysician profile
Richard Dolinar
NPI 1548227028
$411,039.57
in general payments reported to CMS, 2019-2025
23 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145K · 2020: $55K · 2021: $40K · 2022: $69K · 2023: $52K · 2024: $19K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Travel and Lodging: $6,219 · Food and Beverage: $5,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,525.00 |
| Travel and Lodging | $6,219.34 |
| Food and Beverage | $5,185.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $342,887.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $36,664.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,329.02 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $6,554.63 | 2019-2025 | Lokelma, Farxiga |
| Medtronic, INC. | $1,874.47 | 2023-2024 | Minimed 780g |
| Tandem Diabetes Care, INC. | $1,500.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $1,084.34 | 2019-2025 | |
| Insulet Corporation | $942.67 | 2019-2024 | Omnipod |
| Abbott Laboratories | $708.17 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Amgen INC. | $647.75 | 2019-2025 | Evenity, Tepezza, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $210.33 | 2023 | |
| Janssen Pharmaceuticals, INC | $138.78 | 2019 | |
| Abbvie INC. | $90.05 | 2019 | |
| Gilead Sciences, INC. | $83.20 | 2019 | |
| Mannkind Corporation | $73.64 | 2021-2023 | Afrezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $50.50 | 2024 | Tymlos |
| Xeris Pharmaceuticals, INC. | $43.84 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $40.62 | 2023-2025 | Unithroid |
| Dexcom, INC. | $37.20 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $26.54 | 2025 | Korlym |
| Verity Pharmaceuticals INC. | $21.41 | 2024 | Tlando |
| Nevro Corp. | $16.53 | 2023 | Senza |
| Ascensia Diabetes Care US INC. | $13.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Dolinar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.